Started Development of Flupentixol Dihydrochloride, Melitracen Hydrochloride, Tiemonium Methylsulfate Under Development Eprinomectin & Ivermectin
2023
Product Launch
Launched Closantel Sodium
2022
Portfolio Expansion
Expanded our API product portfolio to include key therapeutic segments such as antiparasitic agents, veterinary antibacterials, acaricides, and anticonvulsants.
Flufenamic Acid, Closantel Base & Methyl Cobalamin IP/JP
2021
Regulatory Certification
Received the Certificate of Source Validation for our API from DGDA, Republic of Bangladesh. We began regular commercial operations in the country.
2020
Global Expansion
Expanded global operations into over 10 countries, including Bangladesh, Vietnam, South Korea, Uruguay, Egypt, South Africa, Pakistan, Japan, and Poland.
2019
Third Product Introduction
Launched our Third Product Amitraz IP/BP/EP
2018
First Product Launch
We launched our 2 products, Tolfenamic Acid BP/EP for anti-inflammatory applications & Marbofloxacin IP/BP/USP Anti-bacterial for Veterinary Industry in the Indian and International Market
2017
Company Establishment
Established in Ahmedabad, Gujarat (India), with a dedicated marketing office in Mumbai, Maharashtra (India).
Our manufacturing facility was approved under Indian State GMP guidelines.
